​The stagnant economy hasn't put a dent in sales of FLUOPTICS© products. Some 300 FLUOPTICS© imaging systems are now in use in more than 20 countries, not only in Europe, but also in the United States, Japan, South Korea, and India. FLUOPTICS© systems put critical information in front of surgeons in real-time during procedures.

Over the past two years, the company has totally cornered the thyroid surgery market—a niche that currently has no competitors. When it was founded, FLUOPTICS© initially commercialized an imaging system for surgical assistance during post-mastectomy breast reconstruction. However, two years ago, the company became the first provider to obtain FDA* approval for its FLUOBEAM®LX parathyroid autofluorescence solution. With FLUOBEAM®LX, the surgeon can see the tiny glands in real time and, ideally, ensure that they are left intact. This is currently the only such system approved in the United States, the world's largest thyroid surgery market, and explains the company's continued growth in challenging times.

FLUOPTICS© hosts monthly webinars with talks by top surgeons, generally attended by several dozen surgeons from around the world. This is just one of the ways in which the startup is promoting its innovative solutions and staying ahead of the market. The company's particularly effective sales funnel includes providing its machines on loan to interested webinar participants. The excellent conversion rate from these webinars helped generate 20% growth in 2020 during a global public health crisis.

The company, which currently has 24 employees, plans to pursue a three-pronged strategy of export sales growth, further miniaturization of its system, and the development of new surgical applications. FLUOPTICS© is planning a significant fundraising round in 2021. Stay tuned for more!

*U.S. Food and Drug Administration